What are the indications, dosing regimen, administration guidelines, and contraindications for intravenous ferric derisomaltose (FDI) in iron‑deficiency anemia?

Ferric Derisomaltose (FDI) for Iron Deficiency Anemia

Ferric derisomaltose is the preferred intravenous iron formulation when single-dose total iron repletion is needed, as it is the only IV iron with FDA approval for total dose infusion and has demonstrated mortality reduction in heart failure patients. 1

Indications

FDI is indicated for iron deficiency anemia in adults across multiple conditions:

• Chronic kidney disease (non-dialysis dependent)
• Inflammatory bowel disease
• Heavy menstrual bleeding/menorrhagia
• Pregnancy
• Congestive heart failure - notably, FDI is the first IV iron formulation to demonstrate statistically significant reduction in cardiovascular death in iron-deficient heart failure patients 1
• Intolerance or inadequate response to oral iron 2

The British Society of Gastroenterology guidelines support IV iron when oral iron is ineffective, poorly tolerated, or in patients with chronic disease, continuing blood loss, impaired absorption, or GI inflammatory pathology 3.

Dosing Regimen

Standard dosing:

• 1000 mg as a single infusion for most patients
• Up to 20 mg/kg (maximum 1500 mg) for weight-based dosing 1
• FDI is the only formulation with FDA labeling for total dose infusion 1

Frequency of administration depends on the underlying cause:

• Single total dose infusion suffices if the cause of iron deficiency has been eliminated
• Multiple administrations necessary for ongoing losses (heavy menstrual bleeding, angiodysplasia, inflammatory bowel disease) or impaired absorption (bariatric surgery, autoimmune gastritis, celiac disease) 1

Administration Guidelines

Preparation:

• Dilute in 100 mL of normal saline
• Infuse over 15-30 minutes 1

No test dose required - a key advantage over older formulations like iron dextran 3

Monitoring protocol:

• Observe during infusion for acute onset of minor infusion reactions (same precautions as other formulations) 1
• Do not check iron parameters within 4 weeks of total dose infusion - circulating iron interferes with assays leading to spurious results 1
• Check CBC and iron parameters (ferritin, TSAT) at 4-8 weeks post-infusion 1
• Hemoglobin should increase within 1-2 weeks and rise by 1-2 g/dL within 4-8 weeks 1
• After Hb normalization: check blood count every 3 months for 12 months, then every 6 months for 2-3 years 3

Target iron parameters:

• Ferritin goal: ≥50 ng/mL (regardless of sex) in absence of inflammation 1
• TSAT <20% indicates absolute or functional iron deficiency 1

Contraindications and Safety

Contraindications per FDA labeling: 2

• Known hypersensitivity to ferric derisomaltose or its components

Safety profile:

• Serious or severe hypersensitivity reactions: 0.3% - extremely low rate 4
• Cardiovascular events: 0.8% in clinical trials 4
• Hypophosphatemia risk is significantly lower than ferric carboxymaltose - only 8.4% developed phosphorus <2.0 mg/dL versus 83.2% with iron sucrose, with no severe hypophosphatemia (≤1.0 mg/dL) in FDI group 5

This lower hypophosphatemia risk is a critical advantage over ferric carboxymaltose, which should be avoided in patients requiring repeat infusions due to treatment-emergent hypophosphatemia 1.

Key Clinical Advantages

FDI offers several practical benefits:

• Single-visit complete iron repletion versus multiple visits required for iron sucrose (up to 5 doses) 4
• More rapid hematological response compared to iron sucrose in first 2 weeks 4
• Lower incidence of adverse events (66.2%) compared to iron sucrose (90.8%) 5
• Reduced healthcare resource utilization and improved adherence by eliminating multiple visits 6

Common Pitfalls to Avoid

1. Underdosing: Real-world data shows mean FDI dose was 1244 mg but mean estimated iron need was 1580 mg, with patients remaining anemic after >65% of courses 7. Calculate and administer the full iron deficit.

2. Premature laboratory testing: Checking iron parameters before 4 weeks post-infusion yields unreliable results 1

3. Substituting ferric carboxymaltose for repeat dosing: FCM causes significant hypophosphatemia with repeated infusions and should be avoided in this setting 1

4. Assuming all IV iron formulations are equivalent: FDI has unique mortality benefits in heart failure and superior phosphate safety profile 1, 5